Eli Lilly's investigational sNSCLC drug meets Ph III endpoint
US drug major Eli Lilly’s (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company said yesterday (August 13) that SQUIRE, a recently completed Phase III study, met its primary endpoint.
The study showed that patients with stage IV metastatic squamous non-small cell lung cancer (NSCLC) experienced increased overall survival (OS) when administered the firm’s necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as a first-line treatment, compared to chemotherapy alone.
Under a restructured deal with development partner Bristol-Myers Squibb (NYSE: BMY), the companies shared costs for developing necitumumab, and, if it is approved, B-MS would have receive 55 % of sales in the USA, Canada and Japan, while Lilly will retain all other revenue (The Pharma Letter January 29, 2010). However, along with its fourth-quarter 2012 financial results, B-MS said it has terminated its agreement for necitumumab with Lilly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze